ITGB3 and breast neoplasm: Moreover, ITGB3 silencing with shRNA reduced tumourigenesis in vitro and in vivo, suggesting that ITGB3 is a candidate therapeutic target for most aggressive breast tumours able to survive under low-oxygen conditions.